These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 33899131)

  • 1. Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
    Chen X; Fang L; Zhu Y; Bao Z; Wang Q; Liu R; Sun W; Du H; Lin J; Yu B; Chen S; Zhou J; Zhou J
    Cancer Immunol Immunother; 2021 Dec; 70(12):3513-3524. PubMed ID: 33899131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
    Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
    JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC.
    Schuurbiers M; Huang Z; Saelee S; Javey M; de Visser L; van den Broek D; Heuvel MVD; Lovejoy AF; Monkhorst K; Klass D
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.
    Si H; Kuziora M; Quinn KJ; Helman E; Ye J; Liu F; Scheuring U; Peters S; Rizvi NA; Brohawn PZ; Ranade K; Higgs BW; Banks KC; Chand VK; Raja R
    Clin Cancer Res; 2021 Mar; 27(6):1631-1640. PubMed ID: 33355200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Nan Z; Guoqing W; Xiaoxu Y; Yin M; Xin H; Xue L; Rong W
    Biomed Res Int; 2021; 2021():1780860. PubMed ID: 33791360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Zhang N; Zhang J; Wang G; He X; Mi Y; Cao Y; Yu X
    Front Oncol; 2022; 12():795933. PubMed ID: 35223476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction performance comparison of biomarkers for response to immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Zhao J; Zhuang W; Sun B; Bai H; Wang Z; Zhong J; Wan R; Liu L; Duan J; Wang J
    Thorac Cancer; 2024 May; 15(13):1050-1059. PubMed ID: 38528429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings.
    Sturgill EG; Misch A; Jones CC; Luckett D; Fu X; Schlauch D; Jones SF; Burris HA; Spigel DR; McKenzie AJ
    Oncologist; 2022 Mar; 27(3):175-182. PubMed ID: 35274716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer.
    Zhang Y; Chang L; Yang Y; Fang W; Guan Y; Wu A; Hong S; Zhou H; Chen G; Chen X; Zhao S; Zheng Q; Pan H; Zhang L; Long H; Yang H; Wang X; Wen Z; Wang J; Yang H; Xia X; Zhao Y; Hou X; Ma Y; Zhou T; Zhang Z; Zhan J; Huang Y; Zhao H; Zhou N; Yi X; Zhang L
    J Immunother Cancer; 2019 Apr; 7(1):98. PubMed ID: 30944026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An exploration of LAF-bTMB as a predictor for the efficacy of immunotherapy combined with chemotherapy in non-small cell lung cancer.
    Zhang S; Yang L; Yang Y; Xin Y; Wang Y
    Thorac Cancer; 2022 Dec; 13(23):3374-3383. PubMed ID: 36274215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB.
    He J; Kalinava N; Doshi P; Pavlick DC; Albacker LA; Ebot EM; Tukachinsky H; Pratt J; Fusaro G; Oxnard GR; Green G; Fabrizio D; Baden J
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38035725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression.
    Giroux Leprieur E; Hélias-Rodzewicz Z; Takam Kamga P; Costantini A; Julie C; Corjon A; Dumenil C; Dumoulin J; Giraud V; Labrune S; Garinet S; Chinet T; Emile JF
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.
    Nie W; Wang ZJ; Zhang K; Li B; Cai YR; Wen FC; Zhang D; Bai YZ; Zhang XY; Wang SY; Cheng L; Zhong H; Liu L; Wang J; Han BH
    BMC Med; 2022 May; 20(1):170. PubMed ID: 35509036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy.
    Araujo DV; Wang A; Torti D; Leon A; Marsh K; McCarthy A; Berman H; Spreafico A; Hansen AR; Razak AA; Bedard PL; Wang L; Plackmann E; Chow H; Bao H; Wu X; Pugh TJ; Siu LL
    JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 34056539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.
    Schenker M; Burotto M; Richardet M; Ciuleanu TE; Gonçalves A; Steeghs N; Schoffski P; Ascierto PA; Maio M; Lugowska I; Lupinacci L; Leary A; Delord JP; Grasselli J; Tan DSP; Friedmann J; Vuky J; Tschaika M; Konduru S; Vemula SV; Slepetis R; Kollia G; Pacius M; Duong Q; Huang N; Doshi P; Baden J; Di Nicola M
    J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39107131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Frigola J; Navarro A; Carbonell C; Callejo A; Iranzo P; Cedrés S; Martinez-Marti A; Pardo N; Saoudi-Gonzalez N; Martinez D; Jimenez J; Sansano I; Mancuso FM; Nuciforo P; Montuenga LM; Sánchez-Cespedes M; Prat A; Vivancos A; Felip E; Amat R
    Mol Oncol; 2021 Apr; 15(4):887-900. PubMed ID: 33342055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782.
    Bar J; Esteban E; Rodríguez-Abreu D; Aix SP; Szalai Z; Felip E; Gottfried M; Provencio M; Robinson A; Fülöp A; Rao SB; Camidge DR; Speranza G; Townson SM; Kobie J; Ayers M; Dettman EJ; Hunkapiller N; McDaniel R; Jung B; Burkhardt D; Mauntz R; Csőszi T
    Lung Cancer; 2024 Apr; 190():107506. PubMed ID: 38422883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
    Sun Y; Duan J; Fang W; Wang Z; Du X; Wang X; Li C; Cai S; Zhao J; Li S; Zhang L; Bai H; Wang J
    BMC Med; 2021 Oct; 19(1):239. PubMed ID: 34615542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.